GERD stands for gastroesophageal reflux disease, a chronic condition where stomach contents repeatedly flow back into the esophagus, causing symptoms or tissue damage. Roughly 9.6% of adults in North America have it at any given time, making it one of the most common digestive disorders. While occasional acid reflux is normal, the “disease” label applies when reflux happens frequently enough to cause persistent symptoms like heartburn, or when it produces visible changes to the esophageal lining.
How Doctors Formally Define GERD
The clinical definition hinges on a measurable concept called acid exposure time, or AET. This is the percentage of a 24-hour monitoring period that the esophagus is exposed to a pH below 4 (meaning it’s acidic). Under the Lyon Consensus 2.0, the current international standard for diagnosis, an AET above 6% is considered pathological and confirms GERD. An AET below 4% effectively rules it out. Values between 4% and 6% fall into an inconclusive zone where doctors need additional information to make the call.
To measure AET, a thin probe is placed in the esophagus, either through the nose or as a small wireless capsule attached to the esophageal wall. The probe records pH levels over one or more days. This test is typically reserved for people whose symptoms don’t clearly point to GERD or who haven’t responded to standard treatment. Most people are diagnosed based on their symptoms and how they respond to acid-suppressing medication, without needing pH monitoring at all.
Erosive vs. Non-Erosive Reflux Disease
Medically, GERD splits into two main categories. Erosive reflux disease (ERD) means an endoscopy reveals visible damage to the esophageal lining: redness, breaks, or ulcers. Non-erosive reflux disease (NERD) means the patient has typical reflux symptoms but the esophagus looks normal on endoscopy. NERD is actually more common, accounting for the majority of GERD cases.
These aren’t just two versions of the same problem. They have distinct clinical profiles. People with NERD are more likely to have heightened sensitivity to even small amounts of acid in the esophagus, and they overlap more frequently with other functional gut conditions like irritable bowel syndrome (found in 44% of NERD patients compared to 15% of ERD patients in one study). They’re also more likely to have psychological symptoms like anxiety. People with ERD, on the other hand, tend to have more structural issues: hiatal hernias are twice as common, and their total acid exposure is measurably higher. This distinction matters because NERD patients often respond less predictably to acid-suppressing drugs, since their symptoms may be driven more by nerve sensitivity than by acid volume.
The Role of the Lower Esophageal Sphincter
The lower esophageal sphincter (LES) is a ring of muscle at the junction where the esophagus meets the stomach. It acts as a one-way valve, opening to let food pass into the stomach and closing to keep stomach contents from flowing back up. In GERD, this valve relaxes at the wrong times or doesn’t maintain enough pressure to stay closed.
Several structures work together to keep this barrier intact: the muscle itself, the diaphragm that wraps around it, and the angle at which the esophagus enters the stomach. A hiatal hernia disrupts this system by pushing the LES up through the diaphragm into the chest cavity. Once there, the sphincter loses the reinforcing squeeze of abdominal pressure and sits instead in a low-pressure environment. This makes it less effective. The phrenoesophageal ligament, a band of connective tissue that normally anchors the LES in place below the diaphragm, stretches or weakens in people who develop hiatal hernias. About 35% of people with erosive reflux disease have a hiatal hernia.
Laryngopharyngeal Reflux: When It Reaches the Throat
When stomach acid travels all the way up the esophagus and reaches the throat, voice box, or nasal passages, the condition is called laryngopharyngeal reflux (LPR). This is sometimes called “silent reflux” because many people with LPR never experience classic heartburn. Instead, the symptoms show up as chronic throat clearing, hoarseness, a persistent cough, or a sensation of something stuck in the throat.
LPR can be harder to diagnose because its symptoms mimic allergies, postnasal drip, and other upper airway conditions. Treatment typically requires more aggressive acid suppression than standard GERD, with twice-daily dosing often proving more effective and less costly in the long run than starting with once-daily treatment.
Complications of Untreated GERD
Chronic acid exposure can cause progressive damage. The most significant long-term complication is Barrett’s esophagus, where the cells lining the lower esophagus change to a type more commonly found in the intestine. This transformation is the body’s attempt to protect itself from constant acid exposure, but it carries a small risk of progressing to esophageal cancer.
For people with Barrett’s who show no precancerous changes, the annual risk of developing esophageal adenocarcinoma is between 0.12% and 0.40%. That risk climbs to around 1% per year if early precancerous changes are present, and exceeds 5% per year with advanced precancerous changes. These numbers are low in absolute terms, but they’re the reason doctors recommend regular monitoring with endoscopy once Barrett’s is identified.
Other complications include esophageal strictures (narrowing from scar tissue that can make swallowing difficult), esophageal ulcers, and dental erosion from acid reaching the mouth.
How GERD Is Treated Medically
Proton pump inhibitors (PPIs) are the cornerstone of medical treatment. These drugs work by blocking the acid-producing pumps in the stomach lining. They’re most effective when taken 30 to 60 minutes before a meal, because they can only shut down pumps that are actively working, and eating triggers pump activity. For once-daily dosing, before breakfast is ideal. For twice-daily dosing, before breakfast and before dinner.
Not all PPIs suppress acid equally. Standardized to the potency of omeprazole (one of the most commonly prescribed), pantoprazole delivers only about a quarter of the acid suppression at its standard dose, while rabeprazole delivers nearly twice as much. This variation explains why some people do well on one PPI but not another.
Lifestyle changes that reduce reflux include elevating the head of the bed, avoiding meals within two to three hours of lying down, losing excess weight, and limiting foods that relax the LES (alcohol, chocolate, peppermint, and fatty foods are common triggers, though individual responses vary widely).
Surgical Options for Refractory GERD
When medication doesn’t adequately control symptoms, or when someone prefers not to take daily medication indefinitely, surgery becomes an option. The traditional approach is fundoplication, where the top of the stomach is wrapped around the lower esophagus to reinforce the sphincter. The Nissen version wraps fully around; the Toupet version wraps partially.
A newer alternative is a magnetic sphincter augmentation device: a ring of small magnetic beads placed around the LES that strengthens its closure while still allowing it to open for swallowing. At five-year follow-up, 75% to 85% of patients with this device had completely stopped taking PPIs, and acid exposure normalized in about 75% of cases. Quality of life scores improved significantly in 84% of patients.
Head-to-head comparisons show the magnetic device and traditional fundoplication produce similar outcomes in reflux control, PPI use, and overall cost (roughly $48,000 to $50,000). The magnetic device does offer shorter operative time and hospital stays (17 hours versus 38 hours), and patients retain the ability to belch and vomit, which can be impaired after fundoplication. The device isn’t suitable for everyone: it’s not approved for people with large hiatal hernias, Barrett’s esophagus with severe erosion, esophageal motility disorders, or a BMI above 35.
Prevalence Around the World
GERD is not equally distributed globally. North America has the highest age-standardized prevalence at about 9,595 per 100,000 people, followed by Western Europe at roughly 8,222 per 100,000. East Asia has the lowest prevalence among studied regions, at about 4,554 per 100,000. However, East Asia, North Africa, the Middle East, and South Asia are seeing the fastest growth in total case numbers, driven by rising obesity rates, aging populations, and dietary shifts toward more processed and high-fat foods.